Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy

NCT00041080 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00041080
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00041080 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2003
Completion date
January 31, 2011
Enrollment
139 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, primary peritoneal cavity cancer, recurrent ovarian epithelial cancer, stage iii ovarian epithelial cancer, stage iv ovarian epithelial cancer